Title:
STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS
Document Type and Number:
WIPO Patent Application WO/2023/205801
Kind Code:
A3
Abstract:
The invention describes novel steroidal compounds, compositions containing the same, and methods of using the same as SREBP inhibitors, as LXR agonists, or as dual modulators of SREBP and LXR, to treat SREBP and/or LXR mediated diseases.
Inventors:
FEULA ANTONIO (US)
SALITURO FRANCESCO (US)
STITES RYAN (US)
SALITURO FRANCESCO (US)
STITES RYAN (US)
Application Number:
PCT/US2023/066095
Publication Date:
January 18, 2024
Filing Date:
April 22, 2023
Export Citation:
Assignee:
ASTEROID THERAPEUTICS (UA)
International Classes:
A61K31/56; A61K9/48; A61K31/565; A61K31/569
Foreign References:
| US20090258847A1 | 2009-10-15 | |||
| US20190345498A1 | 2019-11-14 |
Other References:
LI ET AL.: "A Bacterial Bile Acid Metabolite Modulates Treg Activity through the Nuclear Hormone Receptor NR4A1", CELL HOST MICROBE, vol. 29, no. 9, 2021, pages 1366 - 1377, XP086771274, DOI: 10.1016/j.chom.2021.07.013
MARTINEZ ET AL.: "Synthesis and activity evaluation of a series of cholanamides as modulators of the liver X receptors", BIOORGANIC & MEDICINAL CHEMISTRY., vol. 26, 2018, pages 1092 - 1101, XP085351055, DOI: 10.1016/j.bmc.2018.01.025
MARTINEZ ET AL.: "Synthesis and activity evaluation of a series of cholanamides as modulators of the liver X receptors", BIOORGANIC & MEDICINAL CHEMISTRY., vol. 26, 2018, pages 1092 - 1101, XP085351055, DOI: 10.1016/j.bmc.2018.01.025
Attorney, Agent or Firm:
VANCE, David (US)
Download PDF: